Itama Ranoraya

PT Itama Ranoraya Tbk (IDX: IRRA) is an Indonesian publicly listed company in the healthcare sector, specializing in the distribution of modern, high-tech medical equipment and pharmaceutical products. Established in the early 2000s, the company has grown into a key player in Indonesia's medical device distribution landscape, serving hospitals, clinics, and other health institutions across both the private and public sectors. Its primary commitment is to deliver exceptional customer experiences through what it calls "Hi-Tech Healthcare Solutions." The company's portfolio spans a wide range of medical technologies, including in-vitro diagnostics (IVD), surgical equipment, and pharmaceutical products. Itama Ranoraya has established partnerships with numerous leading national and international healthcare companies, including Oneject, Abbott, Terumo, Medtronic, Vestrost, Ascensia, Becton Dickinson and Company (BD), and Dirui. These partnerships allow the company to bring advanced medical technologies to the Indonesian market. Itama Ranoraya is listed on the Indonesia Stock Exchange under the ticker code IRRA. In its 2025 fiscal year, the company reported revenue of Rp1.1 trillion, a 12.55% increase year-on-year, with net profit rising 23.03% to Rp65.53 billion and a net profit margin of 5.96%. Earnings per share also increased by 20.13%. The company continues to invest in strengthening its distribution infrastructure, with total assets reaching Rp2.43 trillion. Beyond distribution, Itama Ranoraya is actively involved in advancing medical education and community health programs in Indonesia. It participates in medical conferences and courses, such as the 4th Malang Otorhinolaryngology Head and Neck Surgery Course (MAOC) 2025, where it showcased innovations in ENT surgical equipment. The company's vision is to become a dynamic, consistent, and sustainable healthcare company committed to assisting customers with the best service, hi-tech medical devices, and pharmaceutical products.

PT Itama Ranoraya Tbk was established in the early 2000s as a healthcare distribution company in Indonesia. From its inception, the company focused on bringing modern, high-tech medical equipment and pharmaceutical products to the Indonesian market. Over the years, it built a reputation as a reliable partner for both national and international healthcare manufacturers. The company expanded its portfolio through strategic partnerships with leading global healthcare companies. These include Oneject, Abbott, Terumo, Medtronic, Vestrost, Ascensia, Becton Dickinson and Company (BD), and Dirui. Through these collaborations, Itama Ranoraya has been able to distribute a wide range of medical devices, diagnostics, and pharmaceutical products to hospitals, clinics, and other health institutions across Indonesia. In the 2010s, Itama Ranoraya pursued a public listing on the Indonesia Stock Exchange (IDX) under the ticker code IRRA. This move provided the company with access to capital markets to fund its expansion and strengthen its distribution infrastructure. The company has since grown its asset base significantly, reaching Rp2.43 trillion by the end of fiscal year 2025. In recent years, Itama Ranoraya has continued to invest in its distribution network and in advancing medical education. It actively participates in medical conferences and training courses, such as the 4th Malang Otorhinolaryngology Head and Neck Surgery Course (MAOC) in 2025, where it presented innovations in ENT surgical equipment. The company also promotes awareness of in-vitro diagnostics (IVD) as a foundation for accurate diagnosis and health system efficiency. For fiscal year 2025, Itama Ranoraya reported revenue of Rp1.1 trillion, a 12.55% increase from the previous year. Net profit rose 23.03% to Rp65.53 billion, with a net profit margin of 5.96%. Earnings per share increased by 20.13%. The company's total assets reached Rp2.43 trillion, reflecting its strengthened distribution infrastructure. Itama Ranoraya remains committed to its vision of becoming a dynamic, consistent, and sustainable healthcare company serving the Indonesian market.

• 2025

  Reported revenue of Rp1.1 trillion and net profit of Rp65.53 billion for fiscal year 2025.

• 2025

  Participated in the 4th Malang Otorhinolaryngology Head and Neck Surgery Course (MAOC) 2025.

• 2000

  Established in the early 2000s as a healthcare distribution company in Indonesia.

• Listed on the Indonesia Stock Exchange under ticker IRRA.

Reliable healthcare service provider with a customer-oriented approach, delivering hi-tech medical devices and pharmaceutical products to hospitals, clinics, and health institutions in Indonesia.

• In-vitro diagnostics (IVD) equipment and reagents

• ENT surgical equipment

• Pharmaceutical products

• Medical devices from partners such as Abbott, Terumo, Medtronic, BD, Ascensia, Dirui, Oneject

1. 1Itama | Hi-tech Healthcare Solutionsitama.co.id
2. 2About | Itamaitama.co.id
3. 3Products | Itamaitama.co.id
4. 4Itama Ranoraya - Wikidatawikidata.org